<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23284037</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-7755</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>31</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
                <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Declining second primary ovarian cancer after first primary breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>738-43</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2012.43.2757</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Although ovarian cancer incidence rates have declined in the United States, less is known of ovarian cancer trends among survivors of breast cancer. Therefore, we examined second primary ovarian cancers after first primary breast cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Data were obtained from the Surveillance, Epidemiology, and End Results program (1973 to 2008). Standardized incidence ratios (SIRs) were calculated as the observed numbers of ovarian cancers among survivors of breast cancer compared with the expected numbers in the general population. Absolute rates were measured as the incidence rates for second primary ovarian cancer by year of diagnosis of the first primary breast cancer adjusted for age of breast cancer diagnosis and years since diagnosis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">SIRs for second primary ovarian cancer were elevated over the entire study period (SIR, 1.24; 95% CI, 1.2 to 1.3), whereas the absolute rates declined with an estimated annual percentage change near 1% (-1.34% to -0.09% per year). Secular trends for second ovarian cancers were similar after estrogen receptor (ER) -positive and ER-negative breast cancers, whereas the age-specific patterns varied significantly by ER expression (P for interaction &lt; .001). The largest SIR was among women age less than 50 years with ER-negative breast cancer (SIR, 4.35; 95% CI, 3.5 to 5.4).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Persistently elevated SIRs along with decreasing absolute rates over the entire study period suggest that ovarian cancers in both the general population and survivors of breast cancer are declining in parallel, possibly because of common risk factor exposures. Analytic studies are needed to further assess the parallel overall trends and the age-specific interaction by ER expression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schonfeld</LastName>
                    <ForeName>Sara J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berrington de Gonzalez</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Visvanathan</LastName>
                    <ForeName>Kala</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfeiffer</LastName>
                    <ForeName>Ruth M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anderson</LastName>
                    <ForeName>William F</ForeName>
                    <Initials>WF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>Intramural NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>01</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Oncol</MedlineTA>
            <NlmUniqueID>8309333</NlmUniqueID>
            <ISSNLinking>0732-183X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016609">Neoplasms, Second Primary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016012">Poisson Distribution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011960">Receptors, Estrogen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012044">Regression Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018426">SEER Program</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017741">Survivors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23284037</ArticleId>
            <ArticleId IdType="pii">JCO.2012.43.2757</ArticleId>
            <ArticleId IdType="doi">10.1200/JCO.2012.43.2757</ArticleId>
            <ArticleId IdType="pmc">PMC3574269</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Epidemiology. 2000 Mar;11(2):102-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11021604</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2012 Feb 4;379(9814):432-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22152853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2001 May 17;411(6835):390-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11357148</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):995-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11535553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Mar 15;10(6):2029-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15041722</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Epidemiol Community Health. 1984 Mar;38(1):85-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6707569</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biometrics. 1995 Sep;51(3):874-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7548706</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1996 Nov 2;348(9036):1189-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8898035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Occup Environ Med. 2005 Mar;62(3):141-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15723875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2006 Jan;6(1):63-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16372017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2006 May 1;118(9):2285-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16342146</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2007 Dec;106(3):439-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17277968</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2007 Nov 21;99(22):1657-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18000214</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2008 Jan-Feb;14(1):3-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18086272</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1239-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18323547</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2008 May 21;100(10):751-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18477805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer J. 2008 Nov-Dec;14(6):429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19060610</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>MMWR Morb Mortal Wkly Rep. 2011 Mar 11;60(9):269-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21389929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol. 2011 Apr;35(2):112-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20674535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Apr 20;29(12):1564-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21402610</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2011 Jun 1;305(21):2211-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21558506</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2011 Sep 21;103(18):1397-402</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21753181</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22237781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11162945</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>